Difficulties in Establishing the Adverse Effects of β-Casomorphin-7 Released from β-Casein Variants—A Review

β-Casomorphin-7 (BCM-7) is a peptide released through the proteolysis of β-casein (β-CN), which is considered a bioactive peptide displaying evidence of promoting the binding and activation of the μ-opioid receptor located in various body parts, such as the gastrointestinal tract, the immune system...

Full description

Saved in:

Bibliographic Details
Published in:	Foods Vol. 12; no. 17; p. 3151
Main Authors:	de Vasconcelos, Marta Liliane, Oliveira, Luisa Maria F. S, Hill, Jeremy Paul, Vidal, Ana Maria Centola
Format:	Journal Article
Language:	English
Published:	Basel MDPI AG 22-08-2023 MDPI
Subjects:	Amino acids Analysis Antihypertensives Body parts Casein Cattle Central nervous system Dairy products Food science Gastrointestinal system Gastrointestinal tract Genes genotype Genotypes Health risks Hypotheses Immune system In vivo methods and tests Inflammation lactose intolerance Literature reviews Milk Mutation Narcotics opioid Opioid receptors Peptides Physiological aspects Physiological effects Physiological responses Physiology Polymorphism Proteins Proteolysis Review Side effects β-Casomorphin
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	β-Casomorphin-7 (BCM-7) is a peptide released through the proteolysis of β-casein (β-CN), which is considered a bioactive peptide displaying evidence of promoting the binding and activation of the μ-opioid receptor located in various body parts, such as the gastrointestinal tract, the immune system and potentially the central nervous system. The possible effects of BCM-7 on health are a theme rising in popularity due to evidence found in several studies on the modulation of gastrointestinal proinflammatory responses that can trigger digestive symptoms, such as abdominal discomfort. With the advancement of studies, the hypothesis that there is a correlation of the possible effects of BCM-7 with the microbiota–gut–brain axis has been established. However, some studies have suggested the possibility that these adverse effects are restricted to a portion of the population, and the topic is controversial due to the small number of in vivo studies, which makes it difficult to obtain more conclusive results. In addition, a threshold of exposure to BCM-7 has not yet been established to clarify the potential of this peptide to trigger physiological responses at gastrointestinal and systemic levels. The proportion of the population that can be considered more susceptible to the effects of BCM-7 are evidenced in the literature review. The challenges of establishing the adverse effects of BCM-7 are discussed, including the importance of quantifying the BCM-7 release in the different β-CN genotypes. In summary, the reviewed literature provides plausible indications of the hypothesis of a relationship between β-CN A1/BCM-7 and adverse health effects; however, there is need for further, especially in vivo studies, to better understand and confirm the physiological effects of this peptide.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	2304-8158 2304-8158
DOI:	10.3390/foods12173151